APA (7th ed.) Citation

Vogel, M. M. E., Kroeze, S. G. C., Henkenberens, C., Schmidt-Hegemann, N., Kirste, S., Becker, J., . . . Combs, S. E. (2020). Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. European Journal of Nuclear Medicine & Molecular Imaging, 47(10), 2328. https://doi.org/10.1007/s00259-020-04760-8

Chicago Style (17th ed.) Citation

Vogel, Marco M. E., et al. "Prognostic Risk Classification for Biochemical Relapse-free Survival in Patients with Oligorecurrent Prostate Cancer After [68Ga]PSMA-PET-guided Metastasis-directed Therapy." European Journal of Nuclear Medicine & Molecular Imaging 47, no. 10 (2020): 2328. https://doi.org/10.1007/s00259-020-04760-8.

MLA (9th ed.) Citation

Vogel, Marco M. E., et al. "Prognostic Risk Classification for Biochemical Relapse-free Survival in Patients with Oligorecurrent Prostate Cancer After [68Ga]PSMA-PET-guided Metastasis-directed Therapy." European Journal of Nuclear Medicine & Molecular Imaging, vol. 47, no. 10, 2020, p. 2328, https://doi.org/10.1007/s00259-020-04760-8.